Affiliation : Scientific Officer "G", RB&HSD, BARC, Mumbai, India
Title of the Talk/Lab :Role of Flow Cytometry in Drug Discovery and Development
Deepak Sharma obtained PhD in Applied Biology from the Mumbai University (2009). He is working as a Scientist at Bhabha Atomic Research Centre (2001-present). He is Group Leader for Basic Immunology Research at BARC and Associate Professor at Homi Bhabha National Institute, Mumbai. He has done post-doctoral training at McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, WI, USA (2010-2011). He has used multi-color flow cytometry and cell sorting to elucidate the role of immune system in control of breast cancer susceptibility by non-coding DNA. He has developed modified protocols for CD34+ hematopoietic stem cells, staining of intracellular as well as surface antigens on leukocytes, epithelial cells, endothelial cells and cancer cells and effective flow cytometric analysis using minimal amount of reagents. His lab is using flow cytometry for estimation of cell proliferation, mitochondrial and cellular redox homeostasis, surface thiols, intracellular glutathione, apoptosis and T cell differentiation. He has also developed high content screening based protocols for enumeration of lymphoma and lung cancer stem cells. His present research focus is on development of new drugs for increasing the abundance of tissue stem cells, mitigation of radiation injury, treatment of inflammatory disorders and Graft-versus-Host Disease in animal models and translational research. He has 19 years of experience in flow cytometry assay design, protocol development, data acquisition, analysis and biological interpretation of the results.
Lecture: Role of Flow Cytometry in Drug Discovery and Development: This lecture will cover flow cytometry applications in drug development including high throughput screening, identification of drug targets and pharmacodynamics. The lecture will also focus on flow cytometry based assays in pre-clinical efficacy testing, experimental therapeutics and phase I clinical trials.